Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
EMD Serono |
---|---|
Information provided by: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT00093964 |
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Multiforme |
Drug: EMD 121974 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent. |
Enrollment: | 81 |
Study Start Date: | October 2004 |
Estimated Study Completion Date: | December 2008 |
Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: EMD 121974
500 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle. Cycles will be repeated without pause until disease progression or unacceptable toxicity develops
|
2: Experimental |
Drug: EMD 121974
2000 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle. Cycles will be repeated without pause until disease progression or unacceptable toxicity develops.
|
Angiogenesis (growth of new blood vessels) is important for tumor growth. Cilengitide (EMD 121974) inhibits two receptor proteins (proteins on cell surface), called integrins αvβ3 and αvβ5, which appear to be important in the process of angiogenesis. Cilengitide has been shown to inhibit angiogenesis and growth of several different experimental tumors in animals. Some tumors themselves express integrin αvβ3 and use it as a survival factor (e.g. glioblastoma multiforme), so cilengitide might target both endothelial cells (cells of blood vessels) and the tumor itself triggering tumor cell apoptosis (programmed cell death).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294-3280 | |
United States, Arizona | |
Barrow Neurological Institute | |
Phoenix, Arizona, United States, 85013 | |
United States, California | |
UCLA Medical Center | |
Los Angeles, California, United States, 90095 | |
United States, Colorado | |
Denise Damek | |
Aurora, Colorado, United States, 80010 | |
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Indiana | |
Indiana University Medical Center | |
Indianapolis, Indiana, United States, 46202 | |
United States, Massachusetts | |
University of Massachusetts | |
Worcester, Massachusetts, United States, 01655 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10021 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
Good Samaritan Hospital/Tri Health Hatton Center | |
Cincinnati, Ohio, United States, 45206 | |
United States, Texas | |
Baylor University Medical Center at Dallas | |
Dallas, Texas, United States, 75246 | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Vermont | |
University of Vermont/Fletcher Allen Healthcare | |
Burlington, Vermont, United States, 05401 | |
United States, Virginia | |
University of Virginia Health System | |
Charlottesville, Virginia, United States, 22903 |
Principal Investigator: | David Reardon, MD | Duke University |
Responsible Party: | EMD Serono, Inc. ( Dr. Stephen K. Muir, Clinical Trial Manager ) |
Study ID Numbers: | EMD 121974-009 |
Study First Received: | October 7, 2004 |
Last Updated: | March 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00093964 History of Changes |
Health Authority: | United States: Food and Drug Administration |
brain cancer brain tumor |
Neuroectodermal Tumors Brain Neoplasms Glioblastoma Astrocytoma Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Glioblastoma Multiforme Glioma Recurrence Neoplasms, Glandular and Epithelial |
Neuroectodermal Tumors Glioblastoma Neoplasms Neoplasms by Histologic Type Astrocytoma |
Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Glioma Neoplasms, Neuroepithelial Neoplasms, Glandular and Epithelial |